Thalia Therapeutics Plc (AIM:THAT)

London · Delayed Price · Currency is GBP · Price in GBX

0.6500

0.00 (0.00%)

Jul 6, 2026, 4:24 PM GMT

73.33% (1Y)

Market Cap	5.41M +73.3%
Revenue (ttm)	7.26K -0.2%
Net Income	-1.21M
EPS	-0.00
Shares Out	832.28M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.6950
Previous Close	0.6500
Day's Range	0.6000 - 0.7000
52-Week Range	0.3500 - 1.0000
Beta	0.71
Analysts	n/a
Price Target	n/a
Earnings Date	Jul 9, 2026

About Thalia Therapeutics

Thalia Therapeutics Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1979

Employees 3

Stock Exchange London Stock Exchange AIM

Ticker Symbol THAT

Full Company Profile

Financial Performance

In 2025, Thalia Therapeutics's revenue was 7,264, a decrease of -0.25% compared to the previous year's 7,282. Losses were -1.21 million, 13.8% more than in 2024.

Financial Statements